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Abstract 
The first report of in vivo gene delivery to the retina dates back to 1987 when a 
retroviral vector was injected intraocularly in newborn mice. Later came the 
observation that retinal cells could be successfully transduced using adenoviral 
and, then, adeno-associated and lentiviral vectors. By 2000, it had became clear 
that the eye, compared with other organs and tissues, provides a number of 
advantages for in vivo gene therapy with regard to safety, efficacy and route to 
clinical application. This has prompted the development of many successful 
proof-of-concept studies in animal models. The demonstration that sight could 
be restored in a large animal model with a congenital form of blindness was a 
major landmark that opened the door to the first-in-human trials for recessively 
inherited blinding conditions. With these first human studies demonstrating 
safety and some efficacy, retinal gene therapy has now come of age. The rapid 
clinical development of retinal gene therapy has highlighted various new 
challenges, such as management of inflammation and development of new 
vectors that allow optimization. The treatment of patients with advanced 
photoreceptor degeneration or dominantly inherited retinal dystrophies and the 
delivery of large genes, yet given the progress over the last 25 years, the next 
decade promises a bright future for retinal gene therapy. 
 
 
Text 
 
In 1987 the group of Connie Cepko used intraocular delivery of retroviral vectors 
to label rodent retinal cell progenitors with reporter genes.1 Although it was not 
for therapeutic purposes, this study was the first report of in vivo gene delivery 
to the retina. In the last twenty five years, however, there has been a rapid 
expansion of ocular gene delivery for therapeutic purposes. There have been 
significant contributions from many different groups, many of them European. In 
1994 the groups of Beverly Davidson 2 and Stephen Jones 3 observed efficient 
and effective delivery to retinal pigment epithelium (RPE) cells with an 
adenoviral vector. Efficient transduction of photoreceptors, the main target cells 
for gene therapy of inherited retinal degeneration, had to wait for the 
development of what has since become the most effective and widely used vector 
for retinal gene therapy, the adeno-associated viral vector (AAV). Subretinal 
administration of AAV serotype 2 in adult rodents resulted in efficient 
photoreceptor transduction in addition to RPE.4,5 Around the same time, 
administration of newly developed HIV1-based lentiviral vectors to the retina of 
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newborn mice resulted in transduction of RPE and photoreceptor cells.6 
However, even in newborn animals the levels of photoreceptor transduction 
achieved did not reach the levels that could be achieved using AAV-based vectors, 
leaving the latter as the vector of choice for treating most retinal disorders. 
Subsequently, many more naturally occurring7,8,9 or engineered10,11 AAV 
serotypes have been assessed for their ability to transduce the retina with the 
aim of identifying serotypes with advantageous properties: different cell 
tropisms, a greater ability to penetrate the inner retina or to mediate higher 
levels of transgene expression. In general, most AAV vectors are able to mediate 
efficient and life-long transduction of the neuroretina. 
 
From these initial experiments with vectors encoding reporter genes it was 
apparent that the retina offered several advantages in terms of in vivo gene 
delivery when compared to other tissues. Whilst intraocular administrations are 
technically challenging, they allow precise exposure of the tissue to vector.  The 
amount of vector required to obtain substantial retinal exposure is limited, 
minimizing both risks of toxicity and the challenge of large-scale viral vector 
production. The retina is relatively immune-privileged, and the presence of two 
eyes allows the delivery/treatment of one leaving the contralateral eye as an 
intra-individual control. Furthermore, a number of small and large animal 
models of inherited retinal diseases (IRDs) were available to test safety and 
efficacy of retinal gene therapy.  These have been instrumental for the 
development of the many proof-of-concept studies that have been reported since 
the late 1990s. There are dozens of examples of rodent models in which retinal 
structure and function have been substantially improved by subretinal 
administration of viral vectors, most commonly AAV.12 Perhaps the first clear 
proof-of-concept study was carried out by Robin Ali and colleagues who used 
subretinal delivery of an AAV2 vector to deliver a gene encoding the structural 
protein peripherin/rds to restore photoreceptor structure and function .13 14  
 
In the early 2000s, came the observation that efficacy of retinal gene therapy in 
small animals could be replicated in larger species. These studies not only 
demonstrated that scale-up of retinal gene therapy was feasible but also that 
restoration of vision was was evident by observing the behavior of treated 
animals, and thus even the lay public could appreciate the beneficial effect of 
retinal gene therapy in a visually impaired dogs. The pivotal study was 
performed by a group of US investigators, including Bill Hauswirth, Sam 
Jacobson and Gus Aguirre and co-ordinated by Jean Bennett. They demonstrated 
that a single subretinal administration of an AAV2 vector carrying an RPE65 
gene resulted in long term restoration of  night vision in Briard dogs affected by 
Leber congenital amaurosis type 2 (LCA2) caused by RPE65 deficiency.15   
 
In 2005 Hurwitz and colleagues treated retinoblastoma in children using 
intraocular injection of an adenoviral vector carrying a suicide gene.16 The 
procedure was well tolerated, and in several cases resolution of the intravitreous 
tumor seeds was observed. This study represents the first example of an ocular 
gene therapy clinical trial involving a viral vector. It was soon followed by 
several other ocular gene therapy trials. The dramatic improvement in function 
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obtained in the Briard dogs paved the way for the development of the first 
clinical trials of gene therapy for an inherited retinal dystrophy. In 2007-2008 
there were three independent clinical trials of gene therapy for LCA2, involving 
subretinal administration of AAV2 vectors carrying RPE65. The trials, two in the 
US and one in the UK, showed that AAV-mediated gene therapy could be safe and 
effective, with improvements in visual acuity, pupillary reflex, light sensitivity 
and ability to navigate in dim light.17,18,19 Therapeutic benefit was observed 
several weeks after injection and at least some benefit was observed in some 
individuals  even 3 years after treatment. However, two of the trials, reported a 
decline in the level of visual improvement was not sustained long term 20,21 
highlighting the potential need for either higher levels of transgene expression 
or for a wider retinal transduction. This has prompted the development of a new 
trial for LCA2 using  AAV5, a AAV serotype that provides a more efficient retinal 
transduction than AAV2, in combination with an optimized transgene expression 
cassette in order to provide higher levels of RPE65 (NTC02946879, Table I).22 At 
the same time a phase III clinical trial has been developed (NCT00999609, Table 
I) using an original AAV2 vector with the objective of collecting sufficient data to 
obtain market authorization.23 Whatever, the eventual outcome of the current 
efforts to develop an effective gene therapy for LCA2, the positive results 
obtained by different groups has facilitated  a rapid expansion in the number of 
clinical trials of gene therapy for other IRDs. These include conditions  such as 
choroideremia,24 Leber optic neuropathy,25 or Stargardt disease,26 among others 
(Table I) and also common complex diseases, such as age-related macular 
degeneration (AMD) (Table I).27,28  
 
The contribution of European academic groups and companies to the retinal 
gene therapy clinical trials has been substantial.  In the UK, trials of therapies for 
LCA2 (NCT 00643747 and 02781480), X-linked RP (NCT03252847) and CNGB3 
achromatopsia (NCT03001310) have been developed by UCL/Moorfields Eye 
Hospital and MeiraGTx; trials for chroideremia (NCT01461213) and X-linked RP 
(NCT03116113) by The University of Oxford and NightStarX and trials for Usher 
type 1B (NCT01505062), Stargardt disease (NCT01367444) and AMD 
(NCT01301443) by Oxford Biomedica. In France a trial for Leber hereditary 
optic neuropathy (NCT02064569) has been developed by the Institut de la 
Vision, and GenSight in Paris as well as a trial for LCA2 using AAV4 
(NCT01496040) by The University of Nantes. In Germany, a trial  for CNGA3 
achromatopsia (NCT02610582) has been developed by groups at the University 
Hospital Tübingen and the Ludwig-Maximilians-University Munich.   
 
Table I. Retinal gene therapy trials (updated on June 7th, 2017, from 
Clinicaltrials.gov) 
Disease 
 
Vector Number 
(NCT) 
Notes 
Achromatopsia AAV8-hCARp.hCNGB3 03001310 Phase 1/2, Recruiting 
AAV2tYF-CNGA3 02935517 Phase 1/2, Not yet Recruiting 
AAV2tYF-CNGB3 02599922 Phase 1/2, Recruiting 
AAV8-hCNGA3 02610582 Phase 1/2, Recruiting 
Choroideremia AAV2-hCHM 02341807 Phase 1/2, Recruiting 
AAV2-REP1 02407678 Phase 2, Recruiting 
AAV2-REP1 02553135 Phase 2, Active not recruiting 
AAV2-REP1 01461213 Phase 1/2, Active not recruiting 
AAV2-REP1 02077361 Phase 1/2, Active not recruiting 
AAV2-REP1 02671539 Phase 2, Active not recruiting 
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Leber Congenital Amaurosis 2 AAV2-hRPE65v2 01208389 Phase 1/2 (follow-on), Active not recruiting 
AAV5-OPTIRPE65 02946879 LTFU (Phase 1/2), Recruiting 
AAV2-hRPE65v2-301 00999609 Phase 3, Active not recruiting 
AAV2-hRPE65v2-101 00516477 Phase 1/2, Active not recruiting 
AAV5-OPTIRPE65 02781480 Phase 1, Recruiting 
AAV2.hRPE65p.hRPE65 00643747 Phase 1/2, Completed 
AAV2-hRPE65 00749957 Phase 1/2, Active not recruiting 
AAV2-hRPE65 00481546 Phase 1, Active not recruiting 
AAV2-hRPE65 00821340 Phase 1, Unknown 
AAV4-hRPE65 01496040 Phase 1/2, Completed 
Leber Hereditary Optic Neuropathy scAAV2-P1ND4v2 02161380 Phase 1, Recruiting 
AAV2-ND4 02652780 Phase 3, Active not recruiting 
AAV2-ND4 02652767 Phase 3, Recruiting 
AAV2-ND4 03153293 Phase 2/3, Recruiting 
AAV2-ND4 01267422 Phase 1/2, Completed 
AAV2-ND4 02064569 Phase 1/2, Active not recruiting 
Neovascular/Age-related Macular 
Degeneration 
AAV.sFlt1 01494805 Phase 2a, Unknown 
AAV2-sFLT01 01024998 Phase 1, Active not recruiting 
AAV8-AntiVEGF 03066258 Phase 1, Recruiting 
AAV-CD59 03144999 Phase 1, Recruiting 
LV (Retinostat) 01301443 Phase 1, Completed 
LV (Retinostat) 01678872 Phase 1 FU, Recruiting (by invitation) 
Retinitis Pigmentosa AAV-ChR2 02556736 Phase 1/2, Recruiting 
Stargardt Disease LV (SAR422459) 01367444 Phase 1/2, Recruiting (by Invitation) 
Usher Syndrome Type 1B LV (Ushstat) 01505062 Phase 1/2, Recruiting 
LV (Ushstat) 02065011 Phase 1/2, Recruiting (by Invitation) 
X-linked Retinitis Pigmentosa AAV-RPGR 03116113 Phase 1/2, Recruiting 
 AAV2/5-hRK.RPGR 03252847 Phase 1/2, Recruiting 
X-linked Retinoschisis AAV-RS1 02317887 Phase 1/2, Recruiting 
AAV2tYF-hRS1 02416622 Phase 1/2, Recruiting 
 
The rapid clinical development of gene therapy, including retinal gene therapy, 
suggests that the use of nucleic acids as drugs is finally coming of age. The 
multitude of trials, using various vectors, promoters, administration routes and 
doses will establish the basic toolkit for clinical gene therapy of the retina. Over 
the next couple of year, by assessing and comparing immune responses, vector 
shedding and effects of intraocular vector administration on retinal structure 
and function the safety and efficacy of particular vectors, routes of 
administration and doses will be determined. Whilst initial development in mice 
and dogs has provided a sound starting point for these trials, it is becoming 
increasingly clear that pre-clinical data alone does not necessarily enable 
effective translation of a protocol from animals to humans and for many 
therapies further optimization is likely to be required at the clinical trial stage.  
 
As shown in Table I, the majority of the early trials have been in rare inherited 
disorders, but gene therapy can also be used for more common complex 
disorders. The condition most widely studied with regard to gene therapy has 
been neovascular AMD, since existing, but expensive pharmacological treatments 
had already validated VEGF as an effective target.29 For that reason, the failure of 
the first anti-VEGF gene therapy using AAV-sFlt1 was a disappointment.27 A 
positive outcome should have been achievable, but questionable clinical trial 
design and surgical issues have led to an ambiguous conclusion regarding 
therapeutic efficacy. This set back should not prevent further development of 
this area. The potential for major benefits to patients and socioeconomic benefits 
due to a single administration of a vector to target neovascularization versus 
repeated administration of a pharmacological agent has led to the development 
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of various other anti-angiogenic gene therapy approaches and the initiation of a 
number of early phase clinical trials (table I).(refs) 28,30 
 
Recent and ongoing retinal gene therapy trials are also highlighting some of the 
challenges that the field has to overcome to make this approach widely used. One 
is that subretinal administration of vector may induce irreversible damage to a 
tissue that has been thinned by many years of progressive degeneration. In this 
situation, less invasive intravitreal injections would be preferable. Yet the 
current generation of viral vectors do not cross the retinal layers from the 
vitreous to the photoreceptors. To solve this issue, the groups of Schaffer and 
Flannery set up a strategy based on in vivo directed evolution of libraries of 
thousands of AAV capsid variants that were administered to the vitreous of mice. 
The variants able to cross the retinal layers from the vitreous were isolated from 
photoreceptors. Enrichment in one variant, AAV7M8, occurred through repeated 
cycles of intravitreal injections, followed by photoreceptor harvesting and AAV 
capsid sequence isolation.10,31 As a result, AAV7M8 shows unprecedented ability 
to transduce mouse outer retina from the vitreous.31 Confirming this ability in 
retinas of larger species with thicker physical barriers than mice is ongoing and 
the first results look promising.32 AAV7M8, or other variants with similar 
properties 33,34 may one day allow to avoid subretinal injection of therapeutic 
viral vectors in patients with IRDs. 
 
One particular challenge to achieving a substantial clinical impact in the field of 
retinal gene therapy is the large number of genes involved in IRDs 
(https://sph.uth.edu/retnet/). Development of a generic gene therapy for 
photoreceptor cell loss has thus been a longstanding goal. Animal studies have 
shown that gene transfer of neurotrophic molecules, including CNTF,35 GDNF36,37 
and bFGF,38 or anti-apoptotic proteins, such as XIAP,39 to the retina can prolong 
the photoreceptor cell survival although this does not always lead to 
preservation of remaining vision.40 To date there have been no clinical trials of 
neurotrophic or anti-apoptotic gene therapy, perhaps because implantation of 
encapsulated cells secreting CNTF directly into the vitreous showed a more 
pronounced loss of light sensitivity in the treated eye, that reversed after 
removal of the implant. No long-term evidence of improved vision or preserved 
retinal structure was found.41  
 
One-third of RP patients with a recognizable pattern of inheritance are affected 
by dominant RP of which many are due to toxic gain-of-function mutations 
(https://sph.uth.edu/retnet/). Among these are RHO P23H and P347S mutations 
for which there are useful transgenic mouse models 42,43. Reducing levels of the 
toxic product rather than adding a correct copy of the gene is expected to 
provide significant benefits. The first attempts in this direction used allele-
specific ribozymes to knock-down RHO P23H expression.44 The discovery of RNA 
interference in mammalian cells led to the development by the group of Jane 
Farrar, Trinity College Dublin, and others of AAV-delivered short hairpin RNAs 
(shRNAs) which would knock-down both the wild-type and mutant RHO allele 
coupled with replacement of a RHO cDNA resistant to the shRNA.45 A different 
approach tuses artificial transcriptional repressors developed in the lab of 
Enrico M. Surace that silence RHO expression, again in an allele-independent 
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manner thus requiring supply of a RHO copy that is resistant to silencing.46 
Although pre-clinical results are promising and there are efforts to further 
develop these strategies into the clinic, one has to consider that knocking down 
RHO expression might convert a mild dominant RP into more severe recessive 
conditions that require expression of high levels of rhodopsin, the most 
abundant protein in photoreceptors. 
 
The last decade has also witnessed the development of new tools for genome 
editing that allow efficient engineering of genes in situ. Among these tools are Zn-
finger (ZF) nucleases, TALE nucleases and, more recently, those based on the 
CRISPR-associated RNA-guided Cas9.47 Each of these systems allows precise 
induction of double strand breaks at specific genomic loci that can be 
repaired either by non-homologous end-joining, potentially knocking out specific 
dominant mutant alleles or by homology-directed repair  that corrects the gene 
defect using a donor DNA template. The versatility and efficacy of these systems 
has increased over the years to levels that now reach therapeutic efficacy in the 
retina of animal models.48 However, off-target mutagenesis and the effects of 
prolonged expression of nucleases to terminally differentiated photoreceptors 
need to be carefully evaluated before clinical application.  
 
For a substantial group of IRD patients the ‘standard’ gene therapy protocols 
described above will not be feasible. They are the advanced cases where most if 
not all photoreceptors have been lost to the degenerative process. Optogenetics 
may offer an alternative therapeutic strategy to regenerative medicine for those 
severely damaged retinas with no remaining photoreceptors. Gene transfer of 
bacterial opsins,49,50 or even rhodopsin,51 to post-photoreceptor neurons like 
bipolar or retinal ganglion cells has the potential to convert them in light sensing 
neurons. Although a clinical trial of optogenetic gene therapy is being prepared 
based on Channelrhodopsin2, the current generation of halorhodopsins or 
channelrhodopsins still requires abnormally high light intensities to be 
effectively excited.52,53 The optogenetics field however is constantly developing. 
Improvement of optogenetic tools for ocular therapeutics can be achieved by 
engineering of the channels to display optimised characteristics. Channel 
engineering has been used previously to improve their function as 
neuroscientific tools, e.g. sacrificing light sensitivity to achieve faster channel 
kinetics.54 For therapeutic use, such fast kinetics are not necessary and a channel 
with kinetics equivalent to or somewhat slower than cone phototransduction, is 
likely to display better light sensitivity. Moreover, using different vector 
serotypes it may be possible to transduce bipolar cells rather than ganglion cells 
and achieve more advanced intraretinal processing.  
 
 
One important limitation of AAV vectors, which to date are the most effective 
platform for gene delivery to photoreceptor cells, are their cargo capacity that is 
limited to around 5 kb of DNA. This prevents their application to gene therapy of 
common and severe IRDs like Stargardt disease, Usher IB or LCA10 which are 
due to mutations in genes with a coding sequence larger than 5 kb. To overcome 
this limitation, the labs of Shannon Boye, Alberto Auricchio and Robert McLaren, 
among others, have developed strategies based on dual AAV vectors each 
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packaging one half of a large transgene expression cassette. Subretinal delivery 
of dual AAV vectors results in co-infection of RPE and photoreceptor cells 
followed by dual AAV genome recombination which reconstitutes expression of 
full length transcript and protein. This process can provide in therapeutic levels 
of transgene expression in mouse models of Stargardt disease or Usher IB,55 and 
opens the possibility to treat these conditions with AAV vectors.  
 
Thirty years have passed since the first viral vectors were injected in developing 
retinas to label the various retinal cell types. Since then hundreds of patients 
have received intraocular injections of viral vectors.  There have been few 
adverse effects and already some patients have signs of improved vision, an 
unprecedented observation in conditions where progression towards blindness 
has been always considered inevitable.  Whilst the recent trials have highlighted 
new challenges and it is clear that further optimization and new approaches are 
still required before gene therapy is a routine treatment for the many individuals 
affected by retinal disorders, after 25 years of research involving many 
researchers around the world, including many European researchers, we are 
now seeing light at the end of the tunnel.  
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